Potassium dihydrogen phosphate 1.701% / Potassium hydroxide 0.14% (total potassium 7.5mmol/50ml) / Disodium phosphate dihydrate 667.5mg solution for infusion 50ml pre-filled syringes
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Potassium dihydrogen phosphate + Potassium hydroxide + Disodium phosphate dihydrate
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Potassium dihydrogen phosphate + Potassium hydroxide + Disodium phosphate dihydrate on the MHRA register
Potassium dihydrogen phosphate 1.701% / Potassium hydroxide 0.14% (total potassium 7.5mmol/50ml) / Disodium phosphate dihydrate 667.5mg solution for infusion 50ml pre-filled syringes
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
1945–2026
Showing the 50 most relevant studies, sorted by most relevant.
Frits Zernike
Journal of the Optical Society of America, 1964
J. Jerphagnon, S. K. Kurtz
Physical Review B, 1970
W. P. Mason
Physical Review, 1946
M. Kumar, J. Xie, K. Chittur, et al.
Biomaterials, 1999
D. Singh, K. N. Hareendran, T. Sreenivas, et al.
Hydrometallurgy, 2017
S. Kyrylenko, F. Warchoł, O. Oleshko, et al.
Materials science & engineering. C, Materials for biological applications, 2021
Plasma Electrolytic Oxidation (PEO) is as a promising technique to modify metal surfaces by application of oxide ceramic coatings with appropriate physical, chemical and biological characteristics. Therefore, objective of this research was to find the simplest settings, yet able to produce relevant bioactive implant surfaces layers on Ti implants by means of PEO. We show that an electrolyte containing potassium dihydrogen phosphate as a source of P and either calcium hydroxide or calcium formate as a source of Ca in combination with a chelating agent, ethylenediamine tetraacetic acid (EDTA), is suitable for PEO to deliver coatings with desired properties. We determined surface morphology, roughness, wettability, chemical and phase composition of titanium after the PEO process. To investigate biocompatibility and bacterial properties of the PEO oxide coatings we used microbial and cell culture tests. The electrolyte based on Ca(OH)2 and EDTA promotes active crystallization of apatites after PEO processing of the Ti implants. The PEO layers can increase electrochemical corrosion resistance. The PEO can be potentially used for development of bioactive surfaces with increased support of eukaryotic cells while inhibiting attachment and growth of bacteria without use of antibacterial agents.
Abstract licence: CC BY
F. Y. Wu
Physical Review, 1968
P. S. Peercy
Physical Review Letters, 1973
L. B. Harris, G. J. Vella
The Journal of Chemical Physics, 1973
Kristina Jančaitienė, Rasa Šlinkšienė, Renata Žvirdauskienė
Open Agriculture, 2023
Abstract One of the challenges of the modern world is to improve human nutrition and to safely increase the yield of agricultural production using existing agricultural land. It is clear that sufficient agricultural efficiency cannot be achieved without fertilizers, but fertilizers must cause minimal damage to the soil. Microorganisms, such as spore-forming bacteria, actinomycetes, fungi, algae, and protozoa play an important role in the soil and keep soil healthy. One of the soil substances involved in reactions that take place in plants is cellulose. This study investigated the effect of potassium dihydrogen phosphate (PDP), synthesized (via conversion between potassium chloride and ammonium dihydrophosphate) and granulated with the addition of microcrystalline cellulose (MC), on plants (winter wheat Toras, Lithuania) and soil microorganisms. The data of plants fertilized with pure KH2PO4, ones fertilized with PDP granulated with MC, and grown without fertilizers were compared in this study. Scanning electron microscopy and differential scanning calorimetry analysis were used to characterize the obtained product. One-way analysis of variance was used to evaluate the differences of the mean values between groups. In all cases, the significance level was p ≤ 0.05. The effect of pure KH2PO4 on plant indicators was found to be lower than that of granular PDP with MC. The length of the leaves was 29.63 and 31.20 cm, green mass was 0.471 and 0.763 g, ash mass was 0.015 and 0.019 g, respectively. In addition, granular PDP with MC did not adversely affect the soil microorganisms because the number of any species of bacteria (Spore b., mineral nitrogen assimilating bacteria, cellulose degrading bacteria) did not decrease and a slight increase in the number of Actinomycetes (from 8.5 × 105 to 2.9 × 106 KSV/g) and molds (from 3.0 × 104 to 1.4 × 105 KSV/g) was observed. The granular PDP with MC that we developed and used have better physical properties, higher agrochemical efficiency and cause less harm to soil microorganisms compared to pure PDP.
Abstract licence: CC BY 4.0
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.